160 related articles for article (PubMed ID: 33526378)
1. Ventriculoperitoneal Shunt for CNS Metastasis in Breast Cancer: Clinical Outcomes Based on Intrinsic Subtype.
Kim HK; Lee HS; Heo MH; Kim JY; Ahn JS; Im YH; Lee JI; Park YH
Clin Breast Cancer; 2021 Aug; 21(4):e402-e414. PubMed ID: 33526378
[TBL] [Abstract][Full Text] [Related]
2. Breast cancer patients with brain metastases or leptomeningeal disease: 10-year results of a national cohort with validation of prognostic indexes.
Znidaric T; Gugic J; Marinko T; Gojkovic Horvat A; Paulin Kosir MS; Golo D; Ivanetic Pantar M; Ratosa I
Breast J; 2019 Nov; 25(6):1117-1125. PubMed ID: 31286623
[TBL] [Abstract][Full Text] [Related]
3. Ventriculoperitoneal shunt in patients with leptomeningeal metastasis.
Omuro AM; Lallana EC; Bilsky MH; DeAngelis LM
Neurology; 2005 May; 64(9):1625-7. PubMed ID: 15883329
[TBL] [Abstract][Full Text] [Related]
4. The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases.
Anders CK; Deal AM; Miller CR; Khorram C; Meng H; Burrows E; Livasy C; Fritchie K; Ewend MG; Perou CM; Carey LA
Cancer; 2011 Apr; 117(8):1602-11. PubMed ID: 21472708
[TBL] [Abstract][Full Text] [Related]
5. Leptomeningeal metastases from breast cancer: intrinsic subtypes may affect unique clinical manifestations.
Lee S; Ahn HK; Park YH; Nam DH; Lee JI; Park W; Choi DH; Huh SJ; Park KT; Ahn JS; Im YH
Breast Cancer Res Treat; 2011 Oct; 129(3):809-17. PubMed ID: 21785952
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Factors and Survival According to Tumor Subtype in Women With Breast Cancer Brain Metastases.
Lopes S; Vieira I; Abreu M; Pousa I; Ferreira A; Sousa S; Pereira D
Curr Probl Cancer; 2022 Dec; 46(6):100866. PubMed ID: 36179388
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology.
Griguolo G; Pouderoux S; Dieci MV; Jacot W; Bourgier C; Miglietta F; Firmin N; Conte P; Viala M; Guarneri V; Darlix A
Oncologist; 2018 Nov; 23(11):1289-1299. PubMed ID: 30120164
[TBL] [Abstract][Full Text] [Related]
8. Characteristics and Outcomes of Patients With Breast Cancer With Leptomeningeal Metastasis.
Morikawa A; Jordan L; Rozner R; Patil S; Boire A; Pentsova E; Seidman AD
Clin Breast Cancer; 2017 Feb; 17(1):23-28. PubMed ID: 27569275
[TBL] [Abstract][Full Text] [Related]
9. Leptomeningeal disease and breast cancer: the importance of tumor subtype.
Abouharb S; Ensor J; Loghin ME; Katz R; Moulder SL; Esteva FJ; Smith B; Valero V; Hortobagyi GN; Melhem-Bertrandt A
Breast Cancer Res Treat; 2014 Aug; 146(3):477-86. PubMed ID: 25038877
[TBL] [Abstract][Full Text] [Related]
10. Risk and prognostic factors of breast cancer with liver metastases.
Ji L; Cheng L; Zhu X; Gao Y; Fan L; Wang Z
BMC Cancer; 2021 Mar; 21(1):238. PubMed ID: 33676449
[TBL] [Abstract][Full Text] [Related]
11. Clinical Outcomes, Treatment Patterns, and Health Resource Utilization Among Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutation: A Real-World Retrospective Study.
Quek RGW; Mardekian J
Adv Ther; 2019 Mar; 36(3):708-720. PubMed ID: 30656571
[TBL] [Abstract][Full Text] [Related]
12. Activity of capecitabine for central nervous system metastases from breast cancer.
Gouveia MC; Filho CMH; Morenoc RA; Alves HCBR; Ayres AS; Testa L; Bonadio RC
Ecancermedicalscience; 2023; 17():1638. PubMed ID: 38414937
[TBL] [Abstract][Full Text] [Related]
13. Ventriculoperitoneal shunt for hydrocephalus caused by central nervous system metastasis.
Lee SH; Kong DS; Seol HJ; Nam DH; Lee JI
J Neurooncol; 2011 Sep; 104(2):545-51. PubMed ID: 21274592
[TBL] [Abstract][Full Text] [Related]
14. Lumboperitoneal shunt for the treatment of leptomeningeal metastasis.
Zhang XH; Wang XG; Piao YZ; Wang P; Li P; Li WL
Med Hypotheses; 2015 May; 84(5):506-8. PubMed ID: 25754849
[TBL] [Abstract][Full Text] [Related]
15. [Clinical features and prognosis of patients with first-episode liver metastasis of different molecular subtypes of breast cancer].
Wu SY; Tan Y; Guan YS
Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):422-8. PubMed ID: 27465945
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes of patients with metastatic breast cancer enrolled in phase I clinical trials.
Criscitiello C; Marra A; Morganti S; Zagami P; Gandini S; Esposito A; Curigliano G
Eur J Cancer; 2021 Nov; 157():40-49. PubMed ID: 34474219
[TBL] [Abstract][Full Text] [Related]
17. Metastatic breast cancer subtypes and central nervous system metastases.
Aversa C; Rossi V; Geuna E; Martinello R; Milani A; Redana S; Valabrega G; Aglietta M; Montemurro F
Breast; 2014 Oct; 23(5):623-8. PubMed ID: 24993072
[TBL] [Abstract][Full Text] [Related]
18. Insights from a Long-Term Follow-Up Evaluation of Early Breast Cancer Outcomes by Tumor Subtype.
Zanardi E; Di Meglio A; Boccardo C; Zinoli L; Salvi S; Rubagotti A
Oncol Res Treat; 2020; 43(7-8):362-371. PubMed ID: 32512573
[TBL] [Abstract][Full Text] [Related]
19. The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients.
Stamatovic L; Susnjar S; Gavrilovic D; Minic I; Ursulovic T; Dzodic R
J BUON; 2018; 23(5):1273-1280. PubMed ID: 30570847
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors and clinical outcomes in patients with leptomeningeal metastasis from solid tumors.
Waki F; Ando M; Takashima A; Yonemori K; Nokihara H; Miyake M; Tateishi U; Tsuta K; Shimada Y; Fujiwara Y; Tamura T
J Neurooncol; 2009 Jun; 93(2):205-12. PubMed ID: 19043775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
